ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Anti factor VIII antibody test,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
2,1,Hepatitis A,Hepatitis virus infections,Viral infectious disorders,Infec,N
3,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
4,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
5,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
6,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
6,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
7,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
7,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
7,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
9,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
10,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
10,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
11,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
11,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
11,3,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
12,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
12,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
12,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
13,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
13,3,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
14,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
14,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
15,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
16,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
17,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
18,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
19,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
20,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
21,1,Hot flush,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
21,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
21,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
22,1,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
22,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
22,3,Mental impairment,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
22,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
22,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
22,6,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
23,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
23,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
23,3,Photopsia,Visual disorders NEC,Vision disorders,Eye,N
24,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,2,Intermenstrual bleeding,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
25,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
26,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
26,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
27,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
27,2,Faeces pale,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
27,3,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
28,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
29,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
29,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
29,3,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
29,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
29,5,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
30,1,Intra-abdominal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
30,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
31,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
31,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
31,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
32,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
33,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
34,1,Anti factor VIII antibody test,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
35,1,Anti factor VIII antibody test,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
35,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
36,1,Anti factor VIII antibody test,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
37,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
38,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
39,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
39,2,Plasmin inhibitor,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
39,3,Varicella,Herpes viral infections,Viral infectious disorders,Infec,N
40,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
41,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
42,1,Anti factor VIII antibody test,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
43,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
44,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
44,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
44,3,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
44,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
45,1,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
45,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
46,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
47,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
48,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
49,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
49,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
49,3,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
49,4,Pneumomediastinum,Mediastinal disorders,Thoracic disorders (excl lung and pleura),Resp,N
49,5,Pneumothorax,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
49,6,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
50,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
51,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
52,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
53,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
53,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
54,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
54,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
55,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
55,2,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
56,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
57,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
57,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
58,1,Coagulation factor VIII level increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
59,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
60,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
61,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
62,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
63,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
64,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
65,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
65,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
66,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
67,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
67,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
67,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
67,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
68,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
69,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
70,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
70,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
70,3,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
71,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
72,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
73,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
74,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
74,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
75,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
75,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
76,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
76,2,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
77,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
78,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
79,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
80,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
81,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
82,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
82,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
83,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
83,2,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
84,1,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
84,2,Product label confusion,Product confusion errors and issues,Medication errors and other product use errors and issues,Inj&P,N
84,3,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
85,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
86,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
86,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
87,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
87,2,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
87,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
88,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
89,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
90,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
90,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
90,3,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
91,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
92,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
93,1,Catheter site infection,Infections NEC,Infections - pathogen unspecified,Infec,N
93,2,Device breakage,Device physical property and chemical issues,Device issues,Prod,N
93,3,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
94,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
95,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
96,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
96,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
97,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
98,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
98,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
99,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
100,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
101,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
102,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
102,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
102,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
102,4,Headache,Headaches NEC,Headaches,Nerv,N
102,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
102,6,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
103,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
104,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
105,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
106,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
107,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
107,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
107,3,Hangover,Feelings and sensations NEC,General system disorders NEC,Genrl,N
107,4,Headache,Headaches NEC,Headaches,Nerv,N
107,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
108,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
108,2,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
109,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
110,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
111,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
111,2,Hypotonia,Muscle tone abnormal,Neuromuscular disorders,Nerv,N
111,3,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
111,4,Petechiae,Purpura and related conditions,Skin vascular abnormalities,Skin,N
112,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
113,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
113,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
113,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
113,4,Oral candidiasis,Candida infections,Fungal infectious disorders,Infec,N
114,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
114,2,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
115,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
115,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
115,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
115,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
115,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
115,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
116,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
117,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
117,2,Ear discomfort,Ear disorders NEC,Aural disorders NEC,Ear,N
117,3,Feeling hot,Feelings and sensations NEC,General system disorders NEC,Genrl,N
117,4,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
117,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
117,6,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
117,7,Ocular discomfort,Ocular disorders NEC,Eye disorders NEC,Eye,N
117,8,Presyncope,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
118,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
119,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
120,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
120,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
120,3,Dry throat,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
120,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
120,5,Headache,Headaches NEC,Headaches,Nerv,N
120,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
120,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
120,8,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
121,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
121,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
122,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
122,2,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
122,3,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
123,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
123,2,Haematology test abnormal,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
124,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
124,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
125,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
125,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
126,1,Headache,Headaches NEC,Headaches,Nerv,N
126,2,Hyperacusis,Hyperacusia,Hearing disorders,Ear,N
126,3,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
127,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
128,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
129,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
130,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
131,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
132,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
133,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
134,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
135,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
136,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
137,1,Lymphoma,Lymphomas unspecified NEC,Lymphomas NEC,Neopl,N
138,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
139,1,Drug half-life reduced,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
139,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
140,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
140,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
141,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
141,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
141,3,Haemorrhage subcutaneous,Skin haemorrhages,Skin vascular abnormalities,Skin,N
141,4,Increased tendency to bruise,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
142,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
143,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
144,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
144,2,Varicella,Herpes viral infections,Viral infectious disorders,Infec,N
145,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
145,2,Hydrocephalus,Hydrocephalic conditions,Increased intracranial pressure and hydrocephalus,Nerv,N
145,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
146,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
147,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
147,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
147,3,Post procedural haematoma,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
148,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
148,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
148,3,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
149,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
150,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
151,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
152,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
153,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
153,2,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
153,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
154,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
155,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
155,2,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
156,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
157,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
158,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
159,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
160,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
161,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
162,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
163,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
164,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
165,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
166,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
167,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
168,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
169,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
170,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
171,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
171,2,Nasopharyngitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
171,3,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
172,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
173,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
174,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
175,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
176,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
177,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
178,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
179,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
179,2,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
179,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
180,1,Inhibiting antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
181,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
181,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
181,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
181,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
181,5,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
182,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
182,2,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
182,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
182,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
182,5,Haemorrhagic diathesis,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
183,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
183,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
183,3,Dissociation,Dissociative states,Dissociative disorders,Psych,N
183,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
183,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
183,6,Headache,Headaches NEC,Headaches,Nerv,N
183,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
183,8,Throat tightness,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
183,9,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
184,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
184,2,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
184,3,Cardiac flutter,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
184,4,Drug hypersensitivity,"Allergies to foods, food additives, drugs and other chemicals",Allergic conditions,Immun,N
184,5,Heart rate decreased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
184,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
185,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
186,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
187,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
188,1,Coronary artery dissection,Coronary artery disorders NEC,Coronary artery disorders,Card,N
188,2,Coronary artery occlusion,Coronary artery disorders NEC,Coronary artery disorders,Card,N
188,3,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
189,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
190,1,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
190,2,Traumatic haemorrhage,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
191,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
191,2,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
191,3,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
192,1,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
192,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
193,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
194,1,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
194,2,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
195,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
196,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
197,1,Hepatitis C,Hepatitis virus infections,Viral infectious disorders,Infec,N
198,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
198,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
199,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
199,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
200,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
200,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
201,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
202,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
203,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
204,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
204,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
204,3,Periprosthetic fracture,Musculoskeletal procedural complications,Procedural related injuries and complications NEC,Inj&P,N
204,4,Wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
205,1,Skin laceration,Skin injuries NEC,Injuries NEC,Inj&P,N
205,2,Wound haemorrhage,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
206,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
207,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
207,2,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
207,3,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
208,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
209,1,Inhibiting antibodies,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
210,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
210,2,Autism spectrum disorder,Pervasive developmental disorders NEC,Developmental disorders NEC,Psych,N
210,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
211,1,Altered state of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
211,2,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
211,3,Blood pressure immeasurable,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
211,4,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
211,5,Compartment syndrome,Myopathies,Muscle disorders,Musc,N
211,6,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
211,7,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
211,8,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
211,9,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
211,10,Superficial vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
211,11,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
211,12,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
212,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
213,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
213,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
214,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
215,1,Eye haemorrhage,Ocular bleeding and vascular disorders NEC,Ocular haemorrhages and vascular disorders NEC,Eye,N
215,2,Pertussis,Bordetella infections,Bacterial infectious disorders,Infec,N
216,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
217,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
217,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
218,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
219,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
220,1,Coagulation factor VIII level decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
221,1,Medical device site haemorrhage,Complications associated with device NEC,Complications associated with device,Genrl,N
222,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
222,2,Inhibiting antibodies positive,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
223,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
223,2,Crying,General signs and symptoms NEC,General system disorders NEC,Genrl,N
223,3,Delirium,Deliria,Deliria (incl confusion),Psych,N
223,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
223,5,Sudden onset of sleep,Sleep disturbances NEC,Sleep disturbances (incl subtypes),Nerv,N
224,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
224,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
224,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
224,4,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
224,5,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
224,6,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
225,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
226,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
227,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
228,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
229,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
230,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
230,2,Maternal exposure during delivery,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
230,3,Postpartum haemorrhage,Postpartum complications NEC,Postpartum and puerperal disorders,Preg,N
231,1,Anti factor VIII antibody test,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
232,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
233,1,Device related infection,Infections NEC,Infections - pathogen unspecified,Infec,N
234,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
235,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
236,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
237,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
238,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
239,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
240,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
240,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
241,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
241,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
241,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
242,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
243,1,Vein collapse,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
244,1,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
245,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
245,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
245,3,Vascular device infection,Vascular infections,Infections - pathogen unspecified,Infec,N
245,4,Vasodilatation,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
246,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
247,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
248,1,Aortic valve replacement,Cardiac valve therapeutic procedures,Cardiac therapeutic procedures,Surg,N
248,2,Traumatic haemothorax,Chest and respiratory tract injuries NEC,Injuries NEC,Inj&P,N
249,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
250,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
251,1,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
251,2,Postpartum haemorrhage,Postpartum complications NEC,Postpartum and puerperal disorders,Preg,N
251,3,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
252,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
253,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
254,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
255,1,Internal haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
256,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
257,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
258,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
259,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
260,1,Hip fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
261,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
261,2,Intentional overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
262,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
262,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
262,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
262,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
262,5,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
262,6,Tenderness,Pain and discomfort NEC,General system disorders NEC,Genrl,N
263,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
263,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
263,3,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
263,4,Inflammation,Inflammations,General system disorders NEC,Genrl,N
263,5,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
263,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
264,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
264,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
265,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
266,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
266,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
267,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
268,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
269,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
270,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
271,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
272,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
273,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
274,1,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
275,1,Fear,Fear symptoms and phobic disorders (incl social phobia),Anxiety disorders and symptoms,Psych,N
275,2,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
276,1,Anaphylactic shock,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
276,2,Choking,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
276,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
276,4,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
277,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
278,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
279,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
280,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
281,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
282,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
282,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
282,3,Product dispensing issue,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
283,1,Upper limb fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
284,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
284,2,Product preparation issue,Product preparation errors and issues,Medication errors and other product use errors and issues,Inj&P,N
285,1,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
286,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
286,2,Injury,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
286,3,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
287,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
288,1,Road traffic accident,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
289,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
289,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
290,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
291,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
291,2,Synovitis,Synovial disorders,Synovial and bursal disorders,Musc,N
292,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
293,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
294,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
295,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
296,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
297,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
298,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
299,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
300,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
300,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
301,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
301,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
302,1,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
303,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
303,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
304,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
305,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
306,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
307,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
308,1,Hip arthroplasty,Joint therapeutic procedures,Bone and joint therapeutic procedures,Surg,N
309,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
310,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
311,1,Hospitalisation,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
311,2,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
312,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
312,2,Surgery,Therapeutic procedures NEC,Therapeutic procedures and supportive care NEC,Surg,N
313,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
314,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
315,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
316,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
317,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
318,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
319,1,Drug eruption,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
320,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
321,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
322,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
323,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
324,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
325,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
325,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
326,1,Menstrual disorder,Menstruation and uterine bleeding NEC,Menstrual cycle and uterine bleeding disorders,Repro,N
326,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
326,3,Spontaneous haemorrhage,Bleeding tendencies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
327,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
327,2,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
327,3,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
327,4,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
327,5,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
327,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
328,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
329,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
329,2,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
330,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
330,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
330,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
331,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
332,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
333,1,Factor VIII inhibition,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
334,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
335,1,Jugular vein occlusion,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
336,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
337,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
337,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
337,3,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
338,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
338,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
338,3,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
339,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
339,2,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
339,3,Prescription drug used without a prescription,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
339,4,Product availability issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
340,1,Extra dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
340,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
340,3,Product distribution issue,Product distribution and storage issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
340,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
341,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
341,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
342,1,Anti factor VIII antibody positive,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
343,1,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
343,2,Product dispensing error,Product dispensing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
344,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
345,1,Haemarthrosis,Arthropathies NEC,Joint disorders,Musc,N
346,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
347,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
347,2,Hepatic infection,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,Y
347,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
348,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
348,2,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,Y
348,3,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
349,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
349,2,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,Y
349,3,Neoplasm,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
350,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
350,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
350,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
350,4,Muscle haemorrhage,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
350,5,Muscle strain,"Muscle, tendon and ligament injuries",Injuries NEC,Inj&P,N
350,6,Testicular neoplasm,Reproductive neoplasms male unspecified malignancy,Reproductive neoplasms male malignant and unspecified,Neopl,N
351,1,Device issue,Device issues NEC,Device issues,Prod,N
351,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
351,3,Injection site mass,Injection site reactions,Administration site reactions,Genrl,N
351,4,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
351,5,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
